anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Among other things, the present disclosure provides various agents. In some embodiments, provided agents can bind to beta-catenin. In some embodiments, the present disclosure provides technologies for modulating beta-catenin functions. In some embodiments, the present disclosure provides technologies for preventing and/or treating conditions, disorders or diseases associated with beta-catenin. In some embodiments, the present disclosure provides designed amino acids which can provide improved properties and/or activities. In some embodiments, the present disclosure provides agents comprising such amino acids.
PURPOSE: The purpose of this study was to evaluate the concordance between patient-reported performance status (prPS) and surgeon-reported performance status (srPS), and to assess the correlation between srPS and prPS and postoperative complications following elective colorectal cancer surgery. Not all patients are deemed suitable for undergoing a surgical procedure. We aimed to assess whether prPS can aid the surgeons' decision-making prior to surgery.
METHODS: In this retrospective study, 524 patients undergoing colorectal cancer surgery were included. prPS were collected via questionnaires, while 30-day postoperative complications were obtained from the Danish Colorectal Cancer Group (DCCG) database. To evaluate the agreement between prPS and srPS, linearly weighted kappa statistics were applied. Rank-biserial correlation analysis was used to calculate the correlation between prPS and srPS with postoperative complications.
RESULTS: In total, there was an approximate 71% concordance between the assessments. Around 17% of the patients rated themselves with a higher PS status than the surgeons, while 13% of the patients rated themselves with a lower PS. Overall postoperative complications, minor surgical complications, and medical complications were all significantly correlated to both srPS and prPS, while only srPS was correlated with major surgical complications. Neither srPS nor prPS were correlated with overall surgical complications (major and minor collapsed).
CONCLUSION: The agreement between prPS and srPS is poor and in nearly one-third of the cases, disagreement occurs. Overall, both prPS and srPS were correlated to postoperative complications, with srPS demonstrated a slightly higher correlation.
With the patient in supine position, three layers of abdominal muscle are visualized using the linear ultrasound probe held with the long axis on the mid-axillary line above the iliac crest. 22G peripheral block needle is introduced in-plane into the fascia between the internal oblique and transversus abdominus muscles and local anesthetic solution (0.5 ml/kg 0.25% bupivacaine) is injected in this plane after a test injection with 0.5 ml of 0.9% NaCl solution to visualize opening of ESP.
Subjects will receive cisplatin 60 mg/m2 IV day 1 plus etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles plus ZD6474 matched placebo oral daily to be continued for the duration of the study. Prophylactic antiemetics will be given at the discretion of the treating investigator.
PURPOSE:To obtain an external drug for skin effective in essentially preventing or curing chapped skin, by using a specific known compound or its salt having an effect to radically improve the water-retaining capability of a corneous layer and optionally a surfactant. CONSTITUTION:The objective external drug for skin contains (A) a compound of formula I (R<1> and R<2> are 10-26C straight- or branched-chain saturated or unsaturated hydrocarbon group) (e.g. a compound wherein both R<1> and R<2> are n-C16H33) or its salt (usable as a cosmetic, especially an alkali metal salt, etc.) or contains the compound A and (B) a surfactant [especially preferably nonionic surfactants, among which glyceryl ether of formula II (R is 8-24C alkyl) is most preferable]. The amount of the surfactant is preferably 0.1-5% based on the whole composition. The agent can be used as an external medicine for skin such as various ointments containing drug-active component or a skin cosmetic such as cosmetic, cream, face lotion, lipstick, foundation or hair dressing.
Imaging cohort. All study participants will be allocated to this arm (single-arm study).Study participants will undergo \[68Ga\]P137 PET/CT scans.
The invention relates to novel biodegrable polyamino acid based materials which can be used for the vectorization of (an) active substance (s) (PA). The invention also relates to novel pharmaceutical, cosmetic, dietary or phytosanitary compositions based on said polyamino acids. The aim of the invention is to provided a novel polymer raw material which can be used for the vectorization of active substances and which can meet all required specifications in said area: biocompatibility, biodegradability, ability to become easily associated with many active substances or the ability to solubilize them, and the ability to release said active substances in vivo. This is achieved in the present invention which primarily relates to polyamino acids comprising aspartic units and/or glutamic units some of which bearing at least one graft, characterized in that at least one of said grafts is joined to an aspartic or glutamic unit by means of an amide bond and in that at least one of said grafts comprises at least one oligoamino acid which is Leu, and/or Ileu, and/or Val, and/or Phe based. Said amide functions ensure better stability with respect to hydrolysis than for similar products of prior art. Advantageously, said polymers can be easily and economically transformed into active substance vectorization particles, said particles being able to form stable aqueous colloidal suspensions.
Stroke is the leading cause of long-term disability in the United States. Approximately 70-88% of persons with ischemic stroke have some degree of motor impairment. A major goal of research in stroke rehabilitation is to harness the ability of the brain to reorganize after neurologic damage has occurred and thus ultimately lead to successful recovery of function. Data from animal and human models have suggested that sensory input plays an important role in motor output, possibly by influencing cortical plasticity. However, in spite of the advances to date, little is known about the extent to which sensory input in the form of peripheral nerve stimulation (PNS) can be successfully combined to physical training, especially in poorly recovered subacute stroke patients. The proposed study will evaluate the effectiveness of sustained PNS coupled with motor training, to improve hand motor function in subacute stroke patients with severe motor deficit. Our preliminary data in chronic stroke patients with severe motor deficit demonstrate that motor function can be substantially enhanced when PNS is paired with motor training. In addition, a separate study in patients with mild motor deficit receiving motor training alone suggests that the optimal therapeutic time window to deliver motor training is within the first year after stroke. The improvement of behavioral motor function was associated with corticomotor reorganization. Therefore, this study proposes to evaluate the effectiveness of sustained PNS paired with motor training, to promote functional motor recovery in subacute stroke patients with severe motor deficit. The central hypothesis is that subacute stroke patients with severe motor deficit receiving PNS and intensive task-oriented therapy will have improved motor function compared to patients receiving sham-PNS and task-oriented therapy, and the degree of this behaviorally-measured effect will correlate with the neurophysiological effect measured by transcranial magnetic stimulation. The investigators plan to accept or reject the central hypothesis by accomplishing two Specific Aims: 1) test the effect of PNS preceding task-oriented therapy on hand motor function, and 2) test the effect of PNS preceding task-oriented therapy on motor map measured by transcranial magnetic stimulation. The long-range goals are: a) to maximize the restoration of hand motor function after stroke, b) to determine the impact of this intervention in activities of daily living, and c) collect solid data to prepare for a future multicenter randomized clinical trial.
The present invention relates to CAR T cells preparation and preparation method, it is made up of following steps：I. the combination of multiple tumour antigens is designed using technique for gene engineering, the combination of described tumour antigen includes a.CD19；And one or two in b.CD20, CD138, CD123, be inserted between 4513 and 4514 positions of carrier sequence for the combination of tumour antigen and constitute CAR by ii., and the base sequence of carrier sequence is as shown in SEQIDNO.1；Iii. CAR is carried out into viral packaging；Iv. CAR is passed through into virus transfection T cell；V. cultivated by culture medium；Vi. the CAR T cells for preparing are mixed with human serum albumin, physiological saline, wherein CAR T cells concentration is 0.5~1 × 10 6 Individual/milliliter, more than 25%, motility rate is more than 95% for CAR positive rates.The present invention compared with the existing technology, by setting up CAR T cells and the Mutiple Targets identification that various different tumour antigens are combined, can improve the recognition capability to tumour cell, it is ensured that killing-efficiency of the T cell to tumour cell.
PURPOSE:To obtain a medical preparation capable of being intravenously administered, having enormously excellent shelf stability, consisting of an emulsion having homogeneous fine oil drop particles containing an Ara-C derivative, an oil component and a phospholipid as an emulsifying agent as main components. CONSTITUTION:A medical preparation consisting of an emulsion having oil drop particles containing 0.01-1W/V% Ara-C derivative shown by the formula (n is 3-24), 5-20W/V% oil component (e.g. soybean oil or safflower oil), 3-20pts.wt. based on 100pts.wt. oil component of a phospholipid (e.g. phosphatidylserine) and further <=5W/V emulsifying auxiliary (nonionic surface active agent having low toxicity) as main components. In production of the medical preparation, Ara-C derivative, and proper amounts of the oil component and the phospholipid are put in a mortar and kneaded to give a homogeneous dispersion system, which is mixed with the residual phospholipid dissolved in the oil component, treated by a homomixer, incorporated with water having dissolved an adduct and emulsified by a heating and jetting type homogenizer.
Current treatments of eosinophilic esophagitis (EoE) aim to eliminate esophageal mucosal inflammation and attenuate, stabilize, or reverse stricture formation. However, our ability to study the long-term course of esophageal strictures in patients with EoE is hampered by the short-term existence of this disease. It is unclear to what degree of control of inflammation is needed to prevent stricture formation. Additionally, identified phenotypes of EoE may ultimately dictate different levels of concern and time intervals for developing fibrosis. Currently, multiple methods are used to monitor patients' disease progression to fibrosis, as symptoms alone do not correlate with disease activity. Endoscopic findings and mucosal histology are used to monitor disease activity, but these focus on improvements in inflammation with inconsistent evaluation of underlying fibrosis. The use of functional lumen impedance planimetry, barium esophagraphy, and endoscopic ultrasound continues to expand in EoE. The rapid advancements in EoE have led to an armamentarium of measuring tools and therapies that holistically characterize disease severity and response to therapy. Nevertheless, our ability to evaluate gross esophageal fibrosis and stricture formation from a transmural rather than mucosal view should be a focus of future investigations because it is essential to monitoring and modulating the trajectory of EoE.
Phenytoin, carbamazepine, and valproic acid, which are among the first-generation AEDs, are prescribed in many countries around the world, including Vietnam. These agents have complicated pharmacokinetics, which may result in alterations in absorption, distribution, and metabolism. This means that, given the same dose, the serum concentration of each drug may vary between patients. The management of epilepsy, as a result, requires inter-professional collaboration to ensure therapeutic optimization. As healthcare professionals, clinical pharmacists play an important role in epilepsy management, which includes establishing a therapeutic drug monitoring (TDM) protocol, adjusting doses, monitoring ADRs, etc.

However, the clinical pharmacy practices in epilepsy management are quite limited in Vietnam. The treatment gap-the proportion of people with epilepsy who are not adequately treated-still remains very high, especially in rural areas (84.7%), which probably results from discontinuing the treatment or refusing to take medications. This shows a need for pharmacist consultations for patients with epilepsy and their family members, as they may be lack information about AEDs or motivation in controlling potential seizures. In addition, the adjustments of antiepileptic drugs by pharmacists are not routine procedures, nor are monitored for effectiveness in many Vietnamese hospitals. This lack of engagement threatens the patients' safety and decreases their quality of life. To address this issue, certain interventions are needed to enable pharmacists to manage patients with epilepsy more systematically. This study was therefore conducted to evaluate the effectiveness of pharmacist interventions in epilepsy treatment at a general hospital in Vietnam.
All participants received eighteen 1 hour sessions (3x/week for 6 weeks) of seated robot-assisted ankle training with the MIT anklebot. Upon analysis, subjects were stratified based on average admission gait speed on the 10 Meter Walk Test at comfortable pace according to clinically established gait speed performance groups: low (\<0.4m/sec), moderate (0.4m/sec-0.8m/sec) and high (\>0.8m/sec) functioning.
<P>PROBLEM TO BE SOLVED: To obtain a creamy skin detergent composition having no sliminess during rinsing, a clean washing, an excellent foaming and foam quality (creamy property).  <P>SOLUTION: The creamy skin detergent composition comprises a fatty acid soap and a cationized polysaccharide having 2-4 mass% nitrogen content. The cationization degree of the cationized polysaccharide is preferably 0.3-0.6. A cationized guar gum is preferable as the cationized polysaccharide. The creamy skin detergent composition may be mixed with an acylamino acid type surfactant or a nonionic polymer.  <P>COPYRIGHT: (C)2008,JPO&INPIT
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to surgery, combustiology, plastic surgery, and can be used for treating a donor's abdominal wound. Full-thickness skin transplant with subcutaneous fat is sampled to abdominal surface fascia, hemostasis, plastic closure of donor wound. After the transplant is taken with separate interrupted sutures, the edges of the donor wound are contracted from the periphery to the center, reducing the area of the wound defect. Performing application of dermal autofibroblasts or allofybroblasts in concentration of 1 million cells in 1 ml to bottom of donor's wound with exposure of 30 minutes. That is followed by simultaneous closure of the wound with a perforated splitter with a perforation factor of 1:2 of skin autografts 0.25 mm thick, which are closed with a meshy atraumatic coating. A vacuum bandage is applied on the donor belly for 5 days at constant pressure of 110 mm Hg with apparatus for vacuum therapy of wounds VivanoTec. On 7th postoperative day, the wound coating is removed.EFFECT: method enables reducing the traumatism of the operation by reducing the area of the donor wound, reducing the area of the split transplant to close the donor wound, reduced volume of blood loss from soft tissues in the area of full-thickness skin transplant, faster adaptation and engraftment of split perforated skin transplants, improved functional and aesthetic results of surgical treatment.1 cl, 26 dwg, 2 ex
BACKGROUND: To report a rare occurrence of pigment epitheliopathy associated with choroidal neovasculization as a first manifestation of systemic lupus erythematosus.
CASE PRESENTATION: A 54-year-old female, with no prior medical history, sought a second opinion due to sudden drop in vision in her right eye to 20/80. Slit lamp examination was normal. Fundus examination revealed the presence of a subretinal hemorrhage in the macular area. Fundus imaging including optical coherence tomography and fluorescein angiography showed multifocal retinal pigment epitheliopathy associated with choroidal neovascularization (CNV). The patient had received an intravitreal injection of Bevacizumab 2 weeks ago. It was decided to complete the loading dose regimen with two additional Bevacizumab injections, and the first injection was done 2 weeks after her presentation. Two weeks later, the patient reported a rash on her cheeks, painful joints, and purpura. Systemic workup revealed positive ANA, anti-cardiolipin antibodies, and decreased complement levels, with negative anti-histone antibodies. This led to the diagnosis of systemic lupus erythematosus (SLE) based on the "Systemic Lupus International Collaborating Clinics" criteria. The patient was treated with 50 mg of prednisolone which was then tapered. 1 month after the third injection, an showed a total resolution of the sub-retinal fluid with an improvement of vision to 20/20. No recurrence was observed during follow-up.
CONCLUSION: Based on the findings from the fundus exam and imaging, systemic symptoms and the blood work-up, we postulate that the pigment epitheliopathy associated with choroidal neovascularization was related to the vaso-occlusive disease at the level of the choroid that can be part of SLE vasculopathy. To our knowledge, this represents the first case in which pigment epitheliopathy and CNV were the primary manifestations of SLE.
The pharmaceutical formulation in the form of an effervescent and/or disintegrating tablet or of instant granules contains at least one active ingredient having an irritating taste and at least one matrix which delays the release of the active ingredient and is present as an intimate mixture with the active ingredient particles or covers said particles and is applied to a carrier. The formulation releases at most 65%, preferably at most 50%, of the active ingredient in aqueous solution at room temperature within about 2 min but more than 70%, preferably at least 80%, of the active ingredient within max. 20 min, preferably max. 15 min, in 0.1N HCl at 38° C. The matrix preferably contains at least one fatty ester and/or one wax, preferably having a melting point between 30° and 45° C., in particular between 32° and 35° C., and/or at least one cellulose derivative and/or at least one polymethacrylate. In particular, the active ingredient is present in an amount of less than 60 mg, preferably less than 10 mg, and the matrix is present in an amount of 1 to 10, preferably 3 to 5, times the amount of active ingredient per tablet or granule dose. For the treatment of diarrhoea by means of loperamide, the matrix additionally contains a mixture which serves to compensate for the electrolyte loss in the body and an amount of alkali metal and/or alkaline earth metal salts, preferably of organic salts, and of chlorides.
The clinical and immunological features after breakthrough infection (BTI) during Omicron wave in patients with chronic hepatitis B virus infection (CHB) are still unclear. A total of 101 patients with CHB from our previous coronavirus disease 2019 (COVID-19) vaccination cohort (NCT05007665), were continued to be followed up at the Second Affiliated Hospital of Chongqing Medical University after BTI, while an additional 39 healthcare workers after BTI were recruited as healthy controls (HCs). Clinical data were collected using questionnaire survey and electronic medical record. Blood samples were used to determine the antibody responses, as well as B and T cell responses. After BTI, the clinical symptoms of COVID-19 were mild to moderate in patients with CHB, with a median duration of 5 days. Compared with HCs, patients with CHB were more susceptible to develop moderate COVID-19. The liver function was not significantly damaged, and HBV-DNA was not activated in patients with CHB after BTI. Patients with CHB could elicit robust antibody responses after BTI (NAbs 13.0-fold, BA.5 IgG: 24.2-fold, respectively), which was also significantly higher than that in every period after vaccination (all p < 0.001), and compared to that in HCs after BTI. The CD4+, cTfh, and CD8+ T cell responses were also augmented in patients with CHB after BTI, while exhibiting comparability to those observed in HCs. In patients with CHB after BTI, the immune imprint was observed in B cell responses, rather than in T cell responses. In conclusion, Omicron breakthrough infection induced mild to moderate COVID-19 symptoms in patients with CHB, without exacerbating the progress of liver diseases. Meanwhile, BTI demonstrated the ability to induce robust antibody and T cell responses in patients with CHB, which was comparable to those observed in HCs.
The skin microbiome is essential for skin barrier function because it inhibits pathogen colonization, and decreased microbiome diversity correlates with increased Staphylococcus aureus (S. aureus) burden and atopic dermatitis (AD) severity. Managing S. aureuss-driven AD in clinical practice remains problematic due to complications such as AD exacerbation, impetigo, abscesses, and invasive infections. This project used a modified Delphi process comprising face-to-face discussions followed by a blinded vote to define 5 final consensus statements. A panel of 6 pediatric dermatologists developed a consensus on S. aureus-driven AD exacerbation, challenges in current treatments for AD with secondary bacterial infections, and new developments to improve patient care and outcomes. The panel's 5 consensus statements provide recommendations for dermatologists, pediatricians, and healthcare providers treating patients with secondary infected AD. These recommendations underscore the importance of recognizing and managing S. aureus skin infection in AD clinical practice and promoting antibiotic stewardship to mitigate resistance. The panel defined a significant unmet need for a single topical AD therapy effective against all symptoms, including pruritus, S. aureus-driven AD exacerbation, infection, and inflammation, across AD severity levels. J Drugs Dermatol. 2024;23(10):825-832. doi:10.36849/JDD.8240.
Many pregnant women experience sleep disorders, and amino acid levels could play a crucial role in affecting maternal sleep. To explore this potential relationship, an accurate and effective UHPLC-MS/MS method has been developed to monitor 18 amino acids in the plasma samples of pregnant women. This method aims to assess how plasma amino acid levels might be linked to sleep disorders during pregnancy. Plasma samples were precipitated with acetonitrile containing 0.2% formic acid. We used 5% seralbumin as the surrogate matrix to establish quantitative curves for amino acid determination in human plasma. The method was validated in both the surrogate matrix and human plasma. The optimized UHPLC-MS/MS method was validated, showing that that the analytes had comparable recovery and negligible matrix effects in both 5% seralbumin and human plasma. The linearity, lower limit of quantification, precision, accuracy, and stability all met the acceptance criteria. The validated method was successfully applied to determination of the plasma levels of 18 amino acids in pregnant women with or without sleep disorders, indicating that alanine, lysine, tryptophan, glutamic acid, and phenylalanine levels had significant changes which may be related to sleep disorders during early pregnancy. An accurate, reliable, and efficient UHPLC-MS/MS method was successfully developed and support to find the specific amino acids as potential biomarkers for sleep disorders in pregnant women.